Investment Thesis
ASP Isotopes exhibits severe financial distress with massive operating losses (-$34.9M) despite 857% revenue growth, indicating fundamentally unprofitable operations unable to monetize growth. The company is burning cash at an alarming rate (-$27.2M free cash flow) and would deplete its cash reserves within 4-5 years at current burn rates, creating an existential viability concern. While the strong current ratio suggests near-term liquidity, the combination of unsustainable losses, negative interest coverage, and deteriorating per-share metrics signals imminent financial restructuring or equity dilution.
ASPI Strengths
- Exceptional revenue growth of 857% YoY demonstrates strong market demand and successful commercialization efforts
- Robust current ratio of 6.14x and quick ratio of 6.10x provide substantial near-term liquidity cushion
- Healthy cash position of $113.9M and conservative debt-to-equity ratio of 0.19x provide financial flexibility for operations
ASPI Risks
- Catastrophic operating margin of -485.3% and net margin of -1342.4% indicate the business model cannot generate profits at scale
- Negative free cash flow of -$27.2M annually with only $113.9M cash reserves suggests cash depletion within 4-5 years without profitability improvement or external funding
- Operating cash flow of -$19.9M combined with negative interest coverage of -3720.2x indicates inability to service debt or fund operations from core business
- EPS deterioration of -28.6% YoY despite revenue growth signals shareholder value destruction and potential for massive dilution from future fundraising
- Seven Form 4 filings in 90 days suggest elevated insider activity potentially indicating distress or governance concerns
Key Metrics to Watch
- Path to operating profitability and timeline to positive operating margins
- Monthly cash burn rate and updated cash runway projections
- Gross margin sustainability and ability to improve through operational scaling
- Operating cash flow inflection point and working capital management efficiency
- Future equity raise announcements and potential dilution impact on shareholders
ASPI Financial Metrics
ASPI Profitability Ratios
ASPI Balance Sheet & Liquidity
ASPI 5-Year Financial Trend
5-Year Trend Summary: ASP Isotopes Inc.'s revenue has grown significantly by 857% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.49 indicates the company is currently unprofitable.
ASPI Growth Metrics (YoY)
ASPI Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.1M | -$7.0M | $-0.12 |
| Q2 2025 | $1.0M | -$7.0M | $-0.24 |
| Q1 2025 | $840.4K | -$7.0M | $-0.12 |
| Q3 2024 | N/A | -$3.6M | $-0.12 |
| Q2 2024 | N/A | -$3.6M | N/A |
| Q1 2024 | N/A | -$3.6M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ASPI Capital Allocation
ASPI SEC Filings
Access official SEC EDGAR filings for ASP Isotopes Inc. (CIK: 0001921865)